Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Perspective TherapeuticsCATX -8.05%30 EV-to-OCF is -1.42 as of Aug. 20, 2026. GuruFocus rates CATX with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 850 Medical Devices & Instruments companies, Perspective Therapeutics ranks better than 65.88% on this metric.
The historical rank and industry rank for Perspective Therapeutics's EV-to-OCF or its related term are showing as below:
CATX'
s EV-to-OCF Range Over the Past 10 Years
Min: -63.16 Med: -3.79 Max: 3.31
Current: -1.42
During the past 13 years, the highest EV-to-OCF of Perspective Therapeutics was 3.31. The lowest was -63.16. And the median was -3.79.
CATX's EV-to-OCF is ranked better than 65.88% of 850
companies
in the Medical Devices & Instruments industry
Industry Median: 7.835
vs CATX: -1.42
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Perspective Therapeutics's PE Ratio (TTM) for today is calculated as:
Perspective Therapeutics's share price for today is $3.20.
Perspective Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.330.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Perspective Therapeutics EV-to-OCF Related Terms
Perspective Therapeutics EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Perspective Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Perspective Therapeutics EV-to-OCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Perspective Therapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Perspective Therapeutics's EV-to-OCF falls into.
Perspective Therapeutics's current Enterprise Value is $132.37 Mil.
Perspective Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-93.07 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Perspective Therapeutics (CATX) has a EV-to-OCF of -1.42 as of Aug. 20, 2026. According to the industry distribution chart, Perspective Therapeutics ranks #290 out of 850 companies in the Medical Devices & Instruments industry, placing it in the top 34.1%.
Is Perspective Therapeutics' EV-to-OCF too high?
Perspective Therapeutics' current EV-to-OCF is -1.42. Based on the distribution chart, Perspective Therapeutics ranks #290 out of 850 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Perspective Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Perspective Therapeutics' EV-to-OCF compare to CV and LAB?
According to the Medical Devices & Instruments industry distribution chart, Perspective Therapeutics ranks #290 out of 850 companies for EV-to-OCF. This puts Perspective Therapeutics in the upper half of its industry. The industry median EV-to-OCF is 7.84. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Devices & Instruments company?
The median EV-to-OCF among Medical Devices & Instruments companies is 7.84, based on 850 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median EV-to-OCF is 7.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Perspective Therapeutics's current EV-to-OCF is -1.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Perspective Therapeutics stock overvalued right now?
Perspective Therapeutics (CATX) has a current EV-to-OCF of -1.42. The current EV-to-OCF is -1.42. Perspective Therapeutics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Perspective Therapeutics (CATX), the current EV-to-OCF is -1.42 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
30GF Score
Get the complete analysis for CATX
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CATX has been successfully added to your 
